Doylestown, PA – Sept. 22, 2017 / Kannalife Sciences, Inc., a pharmaceutical and phyto-medical company, announced today that former three time NFL Pro-Bowl and Kansas City Chiefs placekicker, Nick Lowery, has joined Kannalife corporate advisory board to lead the Company’s initiative on speaking about chronic traumatic encephalopathy (CTE) and Kannalife’s efforts to bring forth a clinically approved treatment for CTE. Kannalife Sciences holds the exclusive license from the federal government to commercialize a cannabinoid patent currently held by the U.S. Government and National Institutes of Health (NIH).
CTE is a degenerative neurological disease caused by repeated head trauma and is only diagnosed with certainty in post-mortem examinations. CTE can lead to symptoms like violent mood swings, depression and other cognitive difficulties. The evidence of severe CTE was seen this week in the latest brain autopsy of NFL player and New England Patriots Tight-End Aaron Hernandez. Currently, CTE can only be definitively diagnosed by direct tissue examination after death. Because there is not much known about this debilitating disease, treatment and prevention options are bleak.
“When Nick and I first met, we drilled down on the great need to bridge the divide being caused by the split narratives regarding CTE – none of which addressed the need for funding clinical research for a treatment. We both believe that through the use of our current license with NIH which centers on the use of cannabidiol as a neuroprotectant, Kannalife can take the lead in working with the NFL to reach the desired goal of helping the many suffering with this terrible disease. Having Nick, a highly respected alumnist of the NFL can not only assist in our objective on the therapeutic side of the equation but also be the face that brings the severity of CTE and concussive injury to the public’s attention with the emphasis placed on solutions rather than irresponsible rhetoric,” said Dean Petkanas, CEO of Kannalife Sciences, Inc.
Nick Lowery will be appearing on Good Morning Arizona talk show at 6:45 a.m. on Saturday September 23, 2017. During these speaking engagements he will be discussing CTE and how devastating it can be on those suffering from this almost invisible disease as well as how KannaLife is looking to work with the NFL to help create a potential safer option for players.
About KannaLife Sciences
Kannalife Sciences, Inc. is a pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”)for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants“ (the “‘507 Patent”). Further, Kannalife has developed its own patented molecules lead by KLS-13019 and was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy”. Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
